US, Australia, and Bengaluru-based Bugworks, a clinical-stage multi-indication therapeutics startup, announced that it has raised $18 million in Series B1 funding.
The round was led by Lightrock India and included existing investors The University of Tokyo Edge Capital (UTEC) Japan, Global Brain Corporation in Japan, 3ONE4Capital India, Acquipharma Holdings SA, IM Holdings BV, and Featherlite Group India. Tejasvi Ravi, representing LightRock India will join the company’s board of directors.
Bugworks plans to use the funding to continue investing in its proprietary drug discovery platforms and identify new drugs for serious, underserved indications.